Results of a key trial of an Eisai and Biogen Alzheimer’s drug have reignited hopes that targeting amyloid beta helps arrest disease progression.
News
STAT+: Pharmalittle: Judge blocks required ACA coverage for preventive care; Supreme Court urged to review skinny label case
A federal judge reversed a major Obamacare provision requiring plans to cover preventive care ranging from disease screenings to pregnancy care. […]
News
STAT+: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’
In some of his first public remarks since getting booed on stage last month over Alzheimer’s drug remarks, Regeneron’s George Yancopoulos acknowledged in an interview he could’ve handled things differently. […]
News
STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
“In taking Amgen but not Bristol, the court may have wanted to wade into this complex area one toe at a time,” one expert said. […]
